Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $59 at RBC Capital
May 10, 2024 6:23 AM EDTRBC Capital analyst Leonid Timashev lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $59.00 (from $61.00) while maintaining a Outperform rating.
The analyst comments "This afternoon BHVN reported 1Q24 earnings and we had a chance to catch up with the mgmt... More
